[ad_1]
On October 12, the US multinational Johnson & Johnson, one of the world’s largest in the pharmaceutical sector, said it had suspended the final phase of the trial of its coronavirus vaccine. Johnson & Johnson explained that they had decided to discontinue because one of the volunteers who had undergone the trial had contracted a disease whose causes are currently unknown.
In September, Johnson & Johnson announced that it had begun the final phase of clinical trials for its vaccine. Although the company was slightly behind other competitors, such as Pfizer, AstraZeneca and Moderna, its phase 3 was the largest organized to date, employing around 60,000 volunteers. Johnson & Johnson said something could be understood about the effectiveness of the vaccine by the end of 2020.
Suspension of experimentation is foreseen by the guidelines if an “unexpected and serious” reaction is reported in volunteers that may in some way be related to the vaccine, although it should be remembered that side effects often occur during clinical trials. Now, an independent safety committee will have to assess whether the disease contracted by the volunteer is related to the vaccine or not.
[ad_2]
